Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal disease caused by the gradual degeneration and death of upper and lower motor neurons. Despite continue efforts, the etiology and pathogenesis of ALS are not well understood yet. The lack of knowledge about molecular and cellular players involved in the neurodegenerative progression of ALS hinders effective therapy development. Several genomicbased studies have been conducted to identify genetic contributors to sporadic ALS (SALS) and new potential pharmacological targets, but these have resulted in short and non-overlapping lists of candidates. In the last few years, our research group has developed the largest whole-genome expression profile database of SALS human samples. We have identified several genes deregulated in the motor cortex of SALS patients and analyzed the role of these genes within deregulated pathways, providing a full molecular portrait of ALS pathogenesis. Some of deregulated genes encode for proteins that are direct or indirect targets of experimental or therapeutic drugs already applied to unrelated diseases. In this review, we focus on the potential role of candidate targets in ALS pathophysiology, highlighting their possible contribution to ALS therapy. The rational selection of the most promising drug targets and related modulatory drugs may provide a starting point for their preclinical or clinical validation and, hopefully, the development of more effective treatments for ALS patients.
Keywords: ALS, drug, pharmacology, pathway, target.
Current Medicinal Chemistry
Title:Selection of Potential Pharmacological Targets in ALS Based on Whole- Genome Expression Profiling
Volume: 22 Issue: 17
Author(s): Giovanna Morello, Francesca Luisa Conforti, Rosalba Parenti, Velia D’Agata and Sebastiano Cavallaro
Affiliation:
Keywords: ALS, drug, pharmacology, pathway, target.
Abstract: Amyotrophic lateral sclerosis (ALS) is a fatal disease caused by the gradual degeneration and death of upper and lower motor neurons. Despite continue efforts, the etiology and pathogenesis of ALS are not well understood yet. The lack of knowledge about molecular and cellular players involved in the neurodegenerative progression of ALS hinders effective therapy development. Several genomicbased studies have been conducted to identify genetic contributors to sporadic ALS (SALS) and new potential pharmacological targets, but these have resulted in short and non-overlapping lists of candidates. In the last few years, our research group has developed the largest whole-genome expression profile database of SALS human samples. We have identified several genes deregulated in the motor cortex of SALS patients and analyzed the role of these genes within deregulated pathways, providing a full molecular portrait of ALS pathogenesis. Some of deregulated genes encode for proteins that are direct or indirect targets of experimental or therapeutic drugs already applied to unrelated diseases. In this review, we focus on the potential role of candidate targets in ALS pathophysiology, highlighting their possible contribution to ALS therapy. The rational selection of the most promising drug targets and related modulatory drugs may provide a starting point for their preclinical or clinical validation and, hopefully, the development of more effective treatments for ALS patients.
Export Options
About this article
Cite this article as:
Morello Giovanna, Conforti Luisa Francesca, Parenti Rosalba, D’Agata Velia and Cavallaro Sebastiano, Selection of Potential Pharmacological Targets in ALS Based on Whole- Genome Expression Profiling, Current Medicinal Chemistry 2015; 22 (17) . https://dx.doi.org/10.2174/0929867322666150408112135
DOI https://dx.doi.org/10.2174/0929867322666150408112135 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Preparation of Hymenialdisine, Analogues and Their Evaluation as Kinase Inhibitors
Current Medicinal Chemistry Multi-Target Directed Compounds with Antioxidant and/or Anti- Inflammatory Properties as Potent Agents for Alzheimer’s Disease
Medicinal Chemistry Targeting Striatal Metabotropic Glutamate Receptor Type 5 in Parkinson’s Disease: Bridging Molecular Studies and Clinical Trials
CNS & Neurological Disorders - Drug Targets Ligands Targeting the Excitatory Amino Acid Transporters (EAATs)
Current Topics in Medicinal Chemistry Acute Effects of Neutrophil-Derived Oxidative Stress on Pulmonary Microvasculature
Current Respiratory Medicine Reviews Molecular Genetics and Biomarkers of Polyglutamine Diseases
Current Molecular Medicine The Effects of Variants in the Parkin, PINK1, and DJ-1 Genes along with Evidence for their Pathogenicity
Current Protein & Peptide Science Molecular Basis of Human Diseases and Targeted Therapy Based on Small-Molecule Inhibitors of ER Stress-Induced Signaling Pathways
Current Molecular Medicine Elevated Homocysteine Levels in Parkinsons Disease: Is there Anything Besides L-Dopa Treatment?
Current Medicinal Chemistry Meet Our Editorial Board Member
Current Alzheimer Research Management of Glia-Mediated Neuroinflammation and Related Patents
Recent Patents on Inflammation & Allergy Drug Discovery The Role of Iron Toxicity in Oxidative Stress-induced Cellular Degeneration in Down Syndrome: Protective Effects of Phenolic Antioxidants
Current Nutrition & Food Science Patent Selections
Recent Patents on Biotechnology Sirtuin Modulators: Mechanisms and Potential Clinical Implications
Current Medicinal Chemistry Synthetic Cannabinoid Receptor Agonists and Antagonists: Implication in CNS Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Noradrenergic System in Down Syndrome and Alzheimer’s Disease A Target for Therapy
Current Alzheimer Research Drug Target Identification for Neuronal Apoptosis Through a Genome Scale Screening
Current Medicinal Chemistry Platelet-Activating Factor (PAF) Antagonists Attenuate Inflammatory- Based Pain: Potential Cellular and Anatomical Sites of PAF Action
Central Nervous System Agents in Medicinal Chemistry Nanomedicine and its Application in Treatment of Microglia-mediated Neuroinflammation
Current Medicinal Chemistry Stem Cells and Translational Medicine: From Research to Clinical Procedures
Current Tissue Engineering (Discontinued)